TABLE 2.

Patient Characteristics (n = 101)

Parameter	Data
Initial characteristics
Initial PSA at diagnosis, median (ng/mL)	6.8 (0.25–33.3)
10	52 (52)
≥10 to <20	10 (10)
≥20	9 (9)
Unknown	30 (30)
Gleason score
≤7	32 (32)
≥8	66 (66)
Unknown	3 (3)
Primary tumor stage
T1–T2	35 (35)
T3–T4	35 (35)
Unknown	31 (31)
Initial NCCN risk group
Low	5 (5)
Intermediate	42 (42)
High	44 (44)
N1	8 (8)
Unknown	2 (2)
Prior treatment
Primary surgery	87 (86)
Surgery only	47 (47)
Surgery + ADT	10 (10)
Surgery + SRT ± ADT	27 (27)
Surgery + SBRT ± ADT	1 (1)
Surgery + chemotherapy ± ADT	2 (2)
Primary RT	14 (14)
RT only	5 (5)
RT + ADT	6 (6)
RT + SBRT ± ADT	2 (2)
RT + chemotherapy ± ADT	1 (1)
PET/CT
Age at PET/CT, median (y)	69 (43–88)
Time between primary treatment and PET/CT, median (y)	4.2 (0.12–18)
ADT within 6 mo before imaging	21 (21)
Serum PSA before PET/CT, median (ng/mL)	1.7 (0.05–140)

NCCN = National Comprehensive Cancer Network; ADT = androgen deprivation therapy; SRT = salvage radiation therapy; RT = radiation therapy; SBRT = stereotactic body radiation therapy.

Qualitative data are expressed as numbers followed by percentages in parentheses; continuous data are expressed as median followed by range in parentheses.